Tissue Kallikrein-Kinin therapy in hypertension and organ damage

Progress in Drug Research

Volumn 69, Issue , 2014, Pages 37-57

  Chao, Julie ^a   Bledsoe, Grant ^a   Chao, Lee ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B2 RECEPTOR; EPITHELIAL SODIUM CHANNEL; GAMMA EPITHELIAL SODIUM CHANNEL; KALLISTATIN; KININ; POTASSIUM; PROTEINASE ACTIVATED RECEPTOR 1; SERINE PROTEINASE INHIBITOR; TISSUE KALLIKREIN; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; BRAIN INJURY; BRAIN ISCHEMIA; CANCER INHIBITION; DIABETES MELLITUS; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIAL PROGENITOR CELL; GAIN OF FUNCTION MUTATION; GENE THERAPY; GENE TRANSFER; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY INJURY; LOSS OF FUNCTION MUTATION; MESENCHYMAL STEM CELL; METASTASIS INHIBITION; NEUROPROTECTION; NONHUMAN; ORGAN INJURY; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; RENAL PROTECTION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; HEART DISEASES; HUMANS; HYPERTENSION; KIDNEY DISEASES; KININS; SIGNAL TRANSDUCTION; TISSUE KALLIKREINS; VASCULAR SYSTEM INJURIES;

EID: 84904394696     PISSN: 0071786X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-319-06683-7_3     Document Type: Article

References (135)

1. Abelous JE, Bardier E (1909) Les substances hypertensives de l'urine humaine normale. C R Soc Biol 66:511-512
2. Agata J, Chao L, Chao J (2002) Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension 40:653-659
3. Araujo RC, Kettritz R, Fichtner I, Paiva AC, Pesquero JB, Bader M (2001) Altered neutrophil homeostasis in kinin B1 receptor-deficient mice. Biol Chem 382:91-95
4. Bergaya S, Meneton P, Bloch-Faure M, Mathieu E, Alhenc-Gelas F, Lévy BI, Boulanger CM (2001) Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice. Circ Res 88:593-599
5. Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash KO, Kuida H, Williams RR (1989) A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 13:3-8
6. Bhoola KD, Figueroa CD, Worthy K (1992) Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44:1-80
7. Bhoola KD, Ramsaroop R, Plendl J, Cassim B, Dlamini Z, Naicker S (2001) Kallikrein and kinin receptor expression in inflammation and cancer. Biol Chem 382:77-89
8. Biyashev D, Tan F, Chen Z, Zhang K, Deddish PA, Erdös EG, Hecquet C (2006) Kallikrein activates bradykinin B2 receptors in absence of kininogen. Am J Physiol Heart Circ Physiol 290:H1244-H1250
9. Blanchard A, Azizi M, Peyrard S, Stern N, Alhenc-Gelas F, Houillier P, Jeunemaitre X (2007) Partial human genetic deficiency in tissue kallikrein activity and renal calcium handling. Clin J Am Soc Nephrol 2:320-325
10. Bledsoe G, Chao L, Chao J (2003) Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 285:H1479-H1488
11. Bledsoe G, Shen B, Yao Y, Zhang JJ, Chao L, Chao J (2006a) Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. Hum Gene Ther 17:545-555
12. Bledsoe G, Crickman S, Mao J, Xia CF, Murakami H, Chao L, Chao J (2006b) Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transpl 21:624-633
13. Bledsoe G, Shen B, Yao YY, Mizell B, Teuton M, Grass D, Chao L, Chao J (2008) Role of tissue kallikrein in the prevention and recovery of gentamicin-induced renal injury. Toxicol Sci 102:433-443
14. Bodin S, Chollet C, Goncalves-Mendes N, Gardes J, Pean F, Heudes D, Bruneval P, Marre M, Alhenc-Gelas F, Bouby N (2009) Kallikrein protects against microalbuminuria in experimental type I diabetes. Kidney Int 76:395-403
15. Calixto JB, Cabrini DA, Ferreira J, Campos MM (2000) Kinins in pain and inflammation. Pain 87:1-5
16. Campbell DJ, Kladis A, Zhang Y, Jenkins AJ, Prior DL, Yii M, Kenny JF, Black MJ, Kelly DJ (2010) Increased tissue kallikrein levels in type 2 diabetes. Diabetologia 53:779-785
17. Chao J, Chao L (1995) Biochemistry, regulation and potential function of kallistatin. Biol Chem Hoppe-Seyler 376:705-713
18. Chao J, Buse J, Shimamoto K, Margolius HS (1981) Kallikrein-induced uterine contraction independent of kinin formation. Proc Natl Acad Sci USA 78:6154-6157
19. Chao J, Tillman DM, Wang M, Margolius HS, Chao L (1986a) Identification of a new tissue kallikrein-binding protein. Biochem J 239:325-331
20. Chao J, Chao L, Woodley CM, Gerald W, Margolius HS (1986b) Active kallikrein, prokallikrein and kallikrein-inhibitor complex. In: Greenbaum LM, Margolius HS (eds) Kinins-IV. Plenum Press, New York
21. Chao J, Chai KX, Chen LM, Xiong W, Chao S, Woodley-Miller C, Wang L, Lu HS, Chao L (1990) Tissue kallikrein-binding protein is a serpin. I. Purification, characterization and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem 265:16394-16401
22. Chao J, Chai KX, Chao L (1996) Tissue kallikrein inhibitors in mammals. Immunopharmacology 32:67-72
23. Chao J, Yang Z, Jin L, Lin KF, Chao L (1997) Kallikrein gene therapy in newborn and adult hypertensive rats. Canadian J Physiol Pharmacol 75:750-756
24. Chao J, Zhang JJ, Lin KF, Chao L (1998a) Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther 9:21-31
25. Chao J, Zhang JJ, Lin KF, Chao L (1998b) Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl-salt sensitive rats. Kidney Int 54:1250-1260
26. Chao J, Li HJ, Yao YY, Shen B, Gao L, Bledsoe G, Chao L (2007) Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity. Hypertension 49:490-497
27. Chao J, Yin H, Gao L, Hagiwara M, Shen B, Yang ZR, Chao L (2008) Tissue kallikrein elicits cardioprotection by direct kinin B2 receptor activation independent of kinin formation. Hypertension 52:715-720
28. Chao J, Shen B, Gao L, Xia CF, Bledsoe G, Chao L (2010) Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem 391:345-355
29. Chen LM, Chao L, Mayfield RK, Chao J (1990) Differential interactions of human kallikreinbinding protein and a1-antitrypsin with human tissue kallikrein. Biochem J 267:79-84
30. Chiang WC, Chien CT, Lin WW, Lin SL, Chen YM, Lai CF, Wu KD, Chao J, Tsai TJ (2006) Early activation of bradykinin B2 receptor aggravates reactive oxygen species generation and renal damage in ischemia/reperfusion injury. Free Radic Biol Med 41:1304-1314
31. Clements JA (1989) The glandular kallikrein family of enzymes: tissue specific expression and hormonal regulation. Endocr Rev 10:393-419
32. Clements JA (1994) The human kallikrein gene family: a diversity of expression and function. Mol Cell Endocrinol 99:C1-C6
33. Couture R, Harrisson M, Vianna RM, Cloutier F (2001) Kinin receptors in pain and inflammation. Eur J Pharmacol 429:161-176
34. Diamandis EP, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, Nelson PS, Shiosaka S, Little S, Lilja H, Stenman UH, Rittenhouse HG, Wain H (2000) New nomenclature for the human tissue kallikrein gene family. Clin Chem 46:1855-1858
35. Ding DY, Lu CZ, Ding MP, Su BH, Chen FA (2007) Multicenter, randomized, double-blinded and placebo-controlled study of acute brain infarction treated by human urinary kallidinogenase. Chin J Neurol 40:306-310
36. Dobrzynski E, Yoshida H, Chao J, Chao L (1999) Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. Immunopharmacology 44:57-65
37. El Moghrabi S, Houillier P, Picard N, Sohet F, Wootla B, Bloch-Faure M, Leviel F, Cheval L, Frische S, Meneton P, Eladari D, Chambrey R (2010) Tissue kallikrein permits early renal adaptation to potassium load. Proc Natl Acad Sci USA 107:13526-13531
38. Elliot R, Nuzum F (1934) Urinary excretion of a depressor substance (kallikrein of Frey and Kraut) in arterial hypertension. Endocrinology 18:462-464
39. Emanueli C, Madeddu P (1999a) Role of the kallikrein-kinin system in the maturation of cardiovascular phenotype. Am J Hypertens 12:988-999
40. Emanueli C, Madeddu P (2004a) Angiogenesis therapy with human tissue kallikrein for the treatment of ischemic diseases. Arch Mal Coeur Vaiss 97:679-687
41. Emanueli C, Maestri R, Corradi D, Marchione R, Minasi A, Tozzi MG, Salis MB, Straino S, Capogrossi MC, Olivetti G, Maddedu P (1999b) Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation 100:2359-2365
42. Emanueli C, Bonaria Salis M, Chao J, Chao L, Agata J, Lin KF, Munaò A, Straino S, Minasi A, Capogrossi MC, Madeddu P (2000) Adenovirus-mediated human tissue kallikrein gene delivery inhibits neointima formation induced by interruption of blood flow in the mouse. Arterioscler Thromb Vasc Biol 20:1459-1466
43. Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Bonaria Salis M, Straino S, Tozzi MG, Smith R, Gaspa L, Bianchini G, Stillo F, Capogrossi MC, Madeddu P (2001) Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 103:125-132
44. Emanueli C, Bonaria Salis M, Pinna A, Stacca T, Milia AF, Spano A, Chao J, Chao L, Sciola L, Madeddu P (2002) Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer. Circulation 106:993-999
45. Emanueli C, Graiani G, Salis MB, Gadau S, Desortes E, Madeddu P (2004b) Prophylactic gene therapy with human tissue kallikrein ameliorates limb ischemia recovery in type 1 diabetic mice. Diabetes 53:1096-1103
46. Gao L, Smith RS, Chen LM, Chai KX, Chao L, Chao J (2010a) Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway. Biol Chem 391:803-812
47. Gao L, Chao L, Chao J (2010b) A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor. Exp Cell Res 316:376-389
48. Gao L, Bledsoe G, Yin H, Shen B, Chao L, Chao J (2013) Tissue kallikrein-modified mesenchymal stem cells provide enhanced protection against ischemic cardiac injury after myocardial infarction. Circ J 77:2134-2144
49. Geiger R, Konig G, Fruhmann G (1981) Inhibition of human tissue (urinary) kallikrein by sera of patients suffering from hereditary a1-antitrypsin (a1-proteinase inhibitor) deficiency. Hoppe- Seyler's Z Physiol Chem 362:1013-1015
50. Griol-Charhbili V, Messadi-Laribi E, Bascands JL, Heudes D, Meneton P, Giudicelli JF, Alhenc- Gelas F, Richer C (2005) Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J 19:1172-1174
51. Griol-Charhbili V, Sabbah L, Colucci J, Vincent MP, Baudrie V, Laude D, Elghozi JL, Bruneval P, Picard N, Meneton P, Alhenc-Gelas F, Richer C (2009) Tissue kallikrein deficiency and renovascular hypertension in the mouse. Am J Physiol Regul Integr Comp Physiol 296:R1385-R1391
52. Hagiwara M, Shen B, Chao L, Chao J (2008) Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum Gene Ther 19:807-819
53. Hashimoto N, Takeyoshi I, Tsutsumi H, Sunose Y, Tokumine M, Totsuka O, Ohwada S, Matsumoto K, Morishita Y (2004) Effects of a bradykinin B(2) receptor antagonist on ischemia-reperfusion injury in a canine lung transplantation model. J Heart Lung Transplant 23:606-613
54. Hecquet C, Tan F, Marcic BM, Erdös EG (2000) Human bradykinin B2 receptor is activated by kallikrein and other serine proteases. Mol Pharmacol 58:828-836
55. Hirawa N, Uehara Y, Suzuki T, Kawabata Y, Numabe A, Gomi T, Ikeda T, Kizuki K, Omata M (1999) Regression of glomerular injury by kallikrein infusion in Dahl salt-sensitive rats is a bradykinin B2-receptor-mediated event. Nephron 81:183-193
56. Horwitz D, Margolius HS, Keiser HR (1978) Effects of dietary potassium and race on urinary excretion of kallikrein and aldosterone in man. J Clin Endocrinol Metab 47:296-299
57. Hunt SC, Hasstedt SJ, Wu LL, Williams RR (1993) A gene-environment interaction between inferred kallikrein genotype and potassium. Hypertension 22:161-168
58. Jin L, Zhang JJ, Chao L, Chao J (1997) Gene therapy in hypertension: Adenovirus-mediated kallikrein gene therapy in hypertensive rats. Hum Gene Ther 8:1753-1761
59. Jin L, Chao L, Chao J (1999) Potassium supplement upregulates the expression of renal kallikrein and bradykinin B2 receptor in SHR. Am J Physiol 276:F476-F484
60. Kakoki M, McGarrah RW, Kim HS, Smithies O (2007) Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci USA 104:7576-7581
61. Kakoki M, Sullivan KA, Backus C, Hayes JM, Oh SS, Hua K, Gasim AM, Tomita H, Grant R, Nossov SB, Kim HS, Jennette JC, Feldman EL, Smithies O (2010) Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proc Natl Acad Sci USA 107:10190-10195
62. Katori M, Majima M (2003) The renal kallikrein-kinin system: Its role as a safety valve for excess sodium intake and its attenuation as a possible etiological factor in salt-sensitive hypertension. Crit Rev Clin Lab Sci 40:43-115
63. Katori M, Majima M (2006) A missing link between a high salt intake and blood pressure increase. J Pharmacol Sci 100:370-390
64. Leone AM, Valgimigli M, Giannico MB, Zaccone V, Perfetti M, D'Amario D, Rebuzzi AG, Crea F (2009) From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells. Eur Heart J 30:890-899
65. Liu Y, Bledsoe G, Hagiwara M, Yang ZR, Shen B, Chao L, Chao J (2010) Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation. Am J Physiol Renal Physiol 298:F1033-F1040
66. Loiola RA, Reis FC, Kawamoto EM, Scavone C, Abdalla DS, Fernandes L, Pesquero JB (2011) Role of vascular Kinin B1 and B2 receptors in endothelial nitric oxide metabolism. Peptides 32:1700-1705
67. Maestri R, Milia AF, Salis MB, Graiani G, Lagrasta C, Monica M, Carradi D, Emanueli C, Madeddu P (2003) Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice. Hypertension 41:1151-1155
68. Mahabeer R, Bhoola K (2000) Kallikrein and kinin receptor genes. Pharmacol Ther 88:77-89
69. Margolius HS (1998) Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease. Clin Rev Allergy Immunol 16:337-349
70. Margolius HS, Geller R, Pisano JJ, Sjoerdsma A (1971) Altered urinary kallikrein excretion in human hypertension. Lancet 2:1063-1065
71. Margolius HS, Horwitz D, Pisano JJ, Keiser HR (1974) Urinary kallikrein excretion in hypertensive man. Relationships to sodium intake and sodium-retaining steroids. Circ Res 35:820-825
72. Medeiros R, Cabrini DA, Ferreira J, Fernandes ES, Mori MA, Pesquero JB, Bader M, Avellar MC, Campos MM, Calixto JB (2004) Bradykinin B1 receptor expression induced by tissue damage in the rat portal vein: a critical role for mitogen-activated protein kinase and nuclear factor-kappaB signaling pathways. Circ Res 94:1375-1382
73. Meneton P, Bloch-Faure M, Hagege AA, Ruetten H, Huang W, Bergaya S, Ceiler D, Gehring D, Martins I, Salmon G, Boulanger CM, Nussberger J, Crozatier B, Gasc JM, Heudes D, Bruneval P, Doetschman T, Menard J, Alhenc-Gelas F (2001) Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci USA 98:2634-2639
74. Miura S, Matsuo Y, Saku K (2003) Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension 41:1118-1123
75. Montanari D, Dobrzynski E, Agata J, Yoshida H, Yin H, Chao J, Chao L (2005) Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocininduced diabetic rats. Diabetes 54:1573-1580
76. Monteiro JS, Blanchard A, Curis E, Chambrey R, Jeunemaitre X, Azizi M (2013) Partial genetic deficiency in tissue kallikrein impairs adaptation to high potassium intake in humans. Kidney Int 84:1271-1277
77. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A (2005) The kallikreinkinin system: current and future pharmacological targets. J Pharmacol Sci 99:6-38
78. Murakami E, Hiwada K, Kokubu T et al. (1989) Effect of oral potassium on urinary kallikrein excretion in essential hypertension. In: Abe K, Moriya H, Fujii S, Kinins V (eds), Plenum Press, New York
79. Murakami H, Yayama K, Chao L, Chao J (1998) Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int 53:1305-1313
80. Murakami H, Yayama K, Miao RQ, Wang C, Chao L, Chao J (1999a) Kallikrein gene transfer inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension 34:164-170
81. Murakami H, Miao RQ, Chao L, Chao J (1999b) Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery. Immunopharmacology 44:137-143
82. Naicker S, Naidoo S, Ramsaroop R, Moodley D, Bhoola K (1999) Tissue kallikrein and kinins in renal disease. Immunopharmacology 44:183-192
83. Nolly H, Carbini LA, Scicli G, Carretero OA, Scicli AG (1994) A local kallikrein-kinin system is present in rat heart. Hypertension 23:919-923
84. Overlack A, Stumpe KO, Ressel C, Kolloch R, Zymzok W, Kruck F (1980) Decreased urinary kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension. Klin Wochenschr 58:37-42
85. Overlack A, Stumpe KO, Kolloch R, Ressel C, Krueck F (1981) Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Results of double blind study. Hypertension 3:118-121
86. Pan ZK, Zuraw BL, Lung CC, Prossnitz ER, Browning DD, Ye RD (1996) Bradykinin stimulates NF-jB activation and interleukin 1beta gene expression in cultured human fibroblasts. J Clin Invest 98:2042-2049
87. Patel AB, Chao J, Palmer LG (2012) Tissue kallikrein activation of the epithelial Na channel. Am J Physiol Renal Physiol 303:F540-F550
88. Picard N, Van Abel M, Campone C, Seiler M, Bloch-Faure M, Hoenderop JG, Loffing J, Meneton P, Bindels RJ, Paillard M, Alhenc-Gelas F, Houillier P (2005) Tissue kallikrein-deficient mice display a defect in renal tubular calcium absorption. J Am Soc Nephrol 16:3602-3610
89. Picard N, Eladari D, El Moghrabi S, Planès C, Bourgeois S, Houillier P, Wang Q, Burnier M, Deschenes G, Knepper MA, Meneton P, Chambrey R (2008) Defective ENaC processing and function in tissue kallikrein-deficient mice. J Biol Chem 283:4602-4611
90. Potier L, Waeckel L, Richer C, Roussel R, Bouby N, Alhenc-Gelas F (2013) Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiency. Biol Chem 394:329-333
91. Price RG (1982) Urinary enzymes, nephrotoxicity and renal disease. Toxicology 23:99-134
92. Regoli D, Rhaleb NE, Drapeau G, Dion S (1990) Kinin receptor subtypes. J Cardiovasc Pharmacol 15:S30-S38
93. Schanstra JP, Neau E, Drogoz P, Arevalo Gomez MA, Lopez Novoa JM, Calise D, Pecher C, Bader M, Girolami JP, Bascands JL (2002) In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 110:371-379
94. Silva JA Jr, Araujo RC, Baltatu O, Oliveira SM, Tschope C, Fink E, Hoffmann S, Plehm R, Chai KX, Chao L, Chao J, Ganten D, Pesquero JB, Bader M (2000) Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J 14:1858-1860
95. Song Q, Chao J, Chao L (1996) Liver-targeted expression of human tissue kallikrein induces hypotension in transgenic mice. Clin Exp Hypertens 18:975-993
96. Souza DG, Pinho V, Pesquero JL, Lomez ES, Poole S, Juliano L, Correa A Jr, de A Castro MS, Teixeira MM (2003) Role of the bradykinin B2 receptor for the local and systemic inflammatory response that follows severe reperfusion injury. Br J Pharmacol 139:129-139
97. Souza DG, Lomez ES, Pinho V, Pesquero JB, Bader M, Pesquero JL, Teixeira MM (2004) Role of bradykinin B2 and B1 receptors in the local, remote, and systemic inflammatory responses that follow intestinal ischemia and reperfusion injury. J Immunol 172:2542-2548
98. Spillmann F, Van Linthout S, Schultheiss HP, Tschöpe C (2006) Cardioprotective mechanisms of the kallikrein-kinin system in diabetic cardiopathy. Curr Opin Nephrol Hypertens 15:22-29
99. Tan Y, Wang B, Keum JS, Jaffa AA (2005) Mechanisms through which bradykinin promotes glomerular injury in diabetes. Am J Physiol Renal Physiol 288:F483-F492
100. Tang SC, Chan LY, Leung JC, Cheng AS, Chan KW, Lan HY, Lai KN (2010) Bradykinin and high glucose promote renal tubular inflammation. Nephrol Dial Transplant 25:698-710
101. Thuringer D, Maulon L, Frelin C (2002) Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitricoxide synthase activation in cardiac capillary endothelial cells. J Biol Chem 277:2028-2032
102. Tobian L (1995) The protective effects of high-potassium diets in hypertension, and the mechanisms by which high-NaCl diets produce hypertension - a personal view. In: Laragh JH, Brenner BM (eds) Hypertension: pathophysiology, diagnosis, and management, 2nd edn. Raven Press, New York
103. Tschöpe C, Walther T, Escher F, Spillmann F, Du J, Altmann C, Schimke I, Bader M, Sanchez-Ferrer CF, Schultheiss HP, Noutsias M (2005) Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. FASEB J 19:2057-2059
104. Uehara Y, Hirawa N, Kawabata Y, Suzuki T, Ohshima N, Oka K, Ikeda T, Goto A, Toyo-oka T, Kizuki K (1994) Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Hypertension 24:770-778
105. Vío CP, Figueroa CD (1987) Evidence for a stimulatory effect of high potassium diet on renal kallikrein. Kidney Int 31:1327-1334
106. Waeckel L, Potier L, Chollet C, Taveau C, Bruneval P, Roussel R, Alhenc-Gelas F, Bouby N (2012) Antihypertensive role of tissue kallikrein in hyperaldosteronism in the mouse. Endocrinology 153:3886-3896
107. Waeckel L, Potier L, Richer C, Roussel R, Bouby N, Alhenc-Gelas F (2013) Pathophysiology of genetic deficiency in tissue kallikrein activity in mouse and man. Thromb Haemost 110:476-483
108. Wang J, Xiong W, Yang Z, Davis T, Dewey MJ, Chao J, Chao L (1994) Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 23:236-243
109. Wang C, Chao L, Chao J (1995) Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 95:1710-1716
110. Wang C, Chao C, Chen LM, Chao L, Chao J (1996) High-salt diet upregulates kininogen and downregulates tissue kallikrein expression in Dahl-SS and SHR rats. Am J Physiol 271:F824-F830
111. Wang DZ, Chao L, Chao J (1997) Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension 29:488-493
112. Wang C, Chao C, Madeddu P, Chao L, Chao J (1998) Central delivery of human tissue kallikrein gene reduces blood pressure in hypertensive rats. Biochem Biophys Res Commun 244:449-454
113. Wang D, Yoshida H, Song Q, Chao L, Chao J (2000) Enhanced renal function in bradykinin B2 receptor transgenic mice. Am J Physiol 278:F484-F491
114. Wang T, Li H, Zhao C, Chen C, Li J, Chao J, Chao L, Xiao X, Wang DW (2004) Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries. Gene Ther 11:1342-1350
115. Wolf WC, Harley RA, Sluce D, Chao L, Chao J (1999) Localization and expression of tissue kallikrein and kallistatin in human blood vessels. J Histochem Cytochem 47:221-228
116. Wolf WC, Yoshida H, Agata J, Chao L, Chao J (2000) Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int 58:730-739
117. Xia CF, Yin H, Borlongan CV, Chao L, Chao J (2004) Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension 43:452-459
118. Xia CF, Bledsoe G, Chao L, Chao J (2005) Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats. Am J Physiol Renal Physiol 289:F622-F661
119. Xia CF, Yin H, Yao YY, Borlongan CV, Chao L, Chao J (2006a) Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther 17:206-219
120. Xia CF, Smith RS Jr, Shen B, Yang ZR, Borlongan CV, Chao L, Chao J (2006b) Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension 47:752-761
121. Xiong W, Chen LM, Woodley-Miller C, Simson JA, Chao J (1990) Identification, purification, and localization of tissue kallikrein in rat heart. Biochem J 267:639-646
122. Xiong W, Tang CQ, Zhou GX, Chao L, Chao J (1992) In vivo catabolism of human kallikreinbinding protein and its complex with tissue kallikrein. J Lab Clin Med 119:514-521
123. Xiong W, Chao J, Chao L (1995) Muscle delivery of human tissue kallikrein gene reduces blood pressure in spontaneously hypertensive rats. Hypertension 25:715-719
124. Yang HYT, Erdos EG, Levin Y (1970) A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta 14:374-376
125. Yao YY, Yin H, Shen B, Chao L, Chao J (2007) Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Regul Pept 140:12-20
126. Yao YY, Yin H, Shen B, Smith RS Jr, Liu Y, Chao L, Chao J (2008) Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3b pathway. Cardiovasc Res 80:354-364
127. Yao Y, Sheng Z, Li Y, Fu C, Ma G, Liu N, Chao J, Chao L (2013) Tissue kallikrein-modified human endothelial progenitor cells implantation improves cardiac function via enhanced activation of Akt and increased angiogenesis. Lab Invest 93:577-591
128. Yayama K, Wang C, Chao L, Chao J (1998) Human tissue kallikrein gene delivery attenuates hypertension, cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 31:1104-1110
129. Yin H, Chao L, Chao J (2005) Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-GSK-3 and Akt-Bad-14-3-3 signaling pathways. J Biol Chem 280:8022-8030
130. Yokoo T, Sakurai K, Ohashi T, Kawamura T (2003) Stem cell gene therapy for chronic renal failure. Curr Gene Ther 3:387-394
131. Yoshida H, Zhang JJ, Chao L, Chao J (2000) Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension 35:25-31
132. Zhang JJ, Bledsoe G, Kato K, Chao L, Chao J (2004) Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int 66:722-732
133. Zhao C, Wang P, Xiao X, Chao J, Chao L, Wang DW, Zeldin DC (2003) Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension 42:1026-1033
134. Zhou G, Chao L, Chao J (1992) Kallistatin: a novel human tissue kallikrein inhibitor: purification, characterization and reactive center sequence. J Biol Chem 267:25873-25880
135. Zinner SH, Margolius HS, Rosner B, Kass EH (1978) Stability of blood pressure rank and urinary kallikrein concentration in childhood: an eight year follow-up. Circulation 58:908-915